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Abstract 
Alcohol use disorder (AUD) persists as a devastating public health problem; widely effective 
pharmacological treatments are needed. Evidence from rodent models suggests that stimulating 
brain receptors for the neuropeptide nociceptin/orphanin FQ (NOP) can decrease ethanol 
drinking. We characterized the effects of the mu opioid peptide (MOP) receptor agonist 
buprenorphine and the buprenorphine analog (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-
epoxy-6,14-ethano-3-hydroxy-6 methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028), 
which stimulates MOP and NOP receptors, in a translational nonhuman primate model of AUD. 
Rhesus monkeys drank a 4% ethanol solution 6 hours per day, 5 days per week via an operant 
behavioral panel in their home cages. To assess behavioral selectivity, monkeys responded via 
a photo-optic switch to earn food pellets. After characterizing the acute effects of BU08028 
(0.001-0.01 mg/kg, i.m.) and buprenorphine (0.003-0.056 mg/kg, i.m.), the drugs were 
administered chronically using a model of pharmacotherapy assessment that incorporates 
clinical aspects of AUD and treatment. Acutely, both drugs decreased ethanol drinking at doses 
that did not affect food-maintained responding. During chronic treatment, effects of BU08028 
and buprenorphine were maintained for several weeks without development of tolerance or 
emergence of adverse effects. BU08028 was approximately 0.5 and 1.0 log units more potent in 
acute and chronic studies, respectively. The selective NOP receptor agonist SCH 221510 also 
selectively decreased ethanol intakes when given acutely (0.03-1.0 mg/kg, i.m.), whereas the 
MOP antagonist naltrexone (1.7-5.6 mg/kg, i.m.) decreased both ethanol intake and food pellets 
delivered. These data provide the first evidence that bifunctional MOP/NOP agonists, which 
may have therapeutic advantages to MOP-selective drugs, can decrease alcohol drinking in 
nonhuman primates. 
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Introduction 
AUD contributes to 88,000 deaths and costs the US ~$250 billion each year, fewer than 10% of 
individuals with AUD receive treatment [1-4]. Existing FDA-approved medications (disulfiram, 
naltrexone and acamprosate) are not widely prescribed due to limited efficacy and adverse 
effects that limit compliance [5,6]. The critical need to develop novel medications for treating 
AUD was emphasized in NIAAA’s 2017-2021 strategic plan. 
 
The NOP receptor (formerly called the “opioid receptor-like” or “ORL1” receptor) is a G protein-
coupled receptor classified in the opioid receptor family based largely on sequence homology 
[7,8]. Neither endogenous opioid peptides nor classical drugs acting at MOP, kappa opioid 
(KOP) or delta opioid (DOP) receptors possess appreciable affinity for NOP receptors [9]. Over 
the last decade, interest in NOP receptor pharmacology has grown following the discovery that 
NOP receptor stimulation can produce analgesia in the absence of side effects associated with 
MOP receptor agonists (e.g. respiratory depression, itch, constipation and addiction). Whereas 
initial work focused on the NOP peptide, non-peptidic agonists have subsequently been 
synthesized [10,11]. More recently “bifunctional” MOP/NOP receptor agonists were developed 
that show promise as non-addictive analgesics [12-15], including the buprenorphine analog 
BU08028 [12,16]. We recently demonstrated the lack of abuse potential of bifunctional agonists, 
including BU08028, in nonhuman primates [12,13]. 
 
Beyond their potential as non-addictive analgesics, recent research has supported the potential 
of NOP receptors as targets for medications to treat other psychiatric conditions including AUD 
[17-19]. For example, NOP receptor agonists can decrease neurochemical and 
neurophysiological effects of ethanol in rats [20,21]. Moreover, administration of the NOP 
peptide or NOP receptor agonists can attenuate behavioral effects of ethanol in rodent models, 
including ethanol self-administration, ethanol seeking and symptoms of ethanol withdrawal [22-
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30]. More recently, it was reported that antagonism or genetic deletion of NOP receptors also 
decreased ethanol drinking [31,32], and that a NOP receptor antagonist reduced heavy drinking 
in a clinical trial [33]. These results suggest that NOP receptor internalization and/or 
desensitization may influence behavioral effects [see 32]. The complex pharmacology of NOP 
receptors merits further research, particularly in the context of AUD medications. 
 
Although important knowledge can be gained about the neuropharmacology of ethanol in 
rodents, the ability to generate clinically relevant phenotypes related to long-term drinking is 
limited. Alternately, nonhuman primates have several advantages that render them a useful 
translational bridge between rodents and potential clinical use. Nonhuman primates are the 
animals most similar to humans in terms of genetics, neuroanatomy and pharmacokinetics and 
show similar neurobiological consequences of long-term alcohol use [34-38]. Moreover, 
monkeys and rodents differ in the distribution and function of brain opioid receptors [39-42]. For 
example, MOP/NOP receptor agonists including BU08028 have been shown to have 
rewarding/reinforcing effects in rodents, but not monkeys [12,13,43,44]. Prominent differences 
in NOP distribution include relatively higher NOP binding in the human and nonhuman primate 
basal ganglia, frontal cortex and amygdala [45,46] in contrast to relatively higher NOP receptor 
binding in the rodent midbrain [47-50]. PET imaging studies using NOP receptor-selective 
radiotracers have been consistent with autoradiographic studies in supporting a similar 
distribution in monkeys and humans [51-53]. Considering the importance of these brain regions 
in addiction, species differences provide further rationale for nonhuman primate studies to 
bridge the gap between rodents and humans.  
 
  
The present studies characterized the effects of the MOP/NOP receptor agonist BU08028 and 
its parent compound buprenorphine in a nonhuman primate model of AUD. Drugs were 
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administered to rhesus monkeys in a self-administration paradigm in which ethanol was freely 
available in six-hour sessions five days per week. To assess whether alterations in consumption 
resulted from behavioral effects unrelated to ethanol reinforcement, monkeys also responded 
using a photo-optic switch to receive food pellets during drinking sessions. At MOP receptors, 
BU08028 and buprenorphine have similar affinities (2.14 and 1.52 nM, respectively) and 
efficacies (21.1 vs. 28.7% compared to DAMGO). At NOP receptors, however, BU08028 has 
~10-fold higher affinity (Ki = 8.5 vs. 77.4 nM) and higher efficacy (48.0 vs. 15.5% compared to 
the NOP peptide [16]). Both drugs block DOP and KOP receptors with affinities similar to their 
MOP receptors affinity [16]. It is important to note, that species differences have been 
documented in the effects of drugs that target MOP and NOP receptors [39-42]. For example, 
although the antinociceptive effects of buprenorphine are mediated in part by NOP receptors in 
rodents, NOP receptors do not appear to play a role in buprenorphine-induced antinociception 
in monkeys [39,54]. Thus the comparison of buprenorphine and BU08028 permits an 
assessment of how the effects of a MOP receptor partial agonist on ethanol consumption differ 
from those of a bifunctional MOP/NOP receptor agonist. In addition, we compared the acute 
effects of these drugs to those of the NOP receptor agonist SCH 221510, which exhibits 217-
fold selectivity in binding and 58-fold selectivity in stimulating NOP vs. MOP receptors [11], and 
the MOP receptor antagonist naltrexone. 
 
Although acute administration of drugs provides an initial indication of potential clinical 
effectiveness, assessment of the effects of chronic treatment is critical for predictive validity with 
respect to the results of clinical trials [55,56]. Considerations include whether tolerance is 
observed to the therapeutic effects of drugs and whether any adverse drug effects emerge. 
Thus we examined the effects of chronic treatment with BU08028 and buprenorphine using a 
translational model of pharmacotherapy evaluation that incorporates aspects of AUD and 
treatment [57-59]. Clinically relevant features of the model include: (1) subjects’ extensive 
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history of ethanol use, (2) an individual-subject design wherein the dose of treatment drug is 
adjusted based on effect rather than a group design in which all monkeys receive identical 
treatment regimens and (3) concurrent measurement of food-maintained responding to monitor 
potential adverse effects. This paradigm has demonstrated good predictive validity with respect 
to the results of clinical trials for cocaine use disorder (57,58,60). 
 
Materials and Methods 
Subjects. Five adult female rhesus monkeys (Macaca mulatta) were housed individually in 0.76 
x 0.83 x 0.83m stainless steel cages in a vivarium maintained at 24˚C and ~30% humidity with a 
12:12 light/dark cycle. All monkeys had been trained to drink a solution of 4% ethanol in water 
using schedule-induced polydipsia [38,61,62] and had been consuming ethanol 5 days per 
week for approximately 1.5 years with a mean (± SD) lifetime intake of 815.5 ± 81.6 g/kg. 
Monkeys were fed 1-g nutritionally complete banana-flavored pellets (Bio-serv; Flemington, NJ), 
delivered during the behavioral session (see below), supplemented with fruit/vegetables. 
Monkeys received enough food to maintain healthy weights as determined by daily visual 
inspection and periodic veterinary examinations. All procedures were approved by the Wake 
Forest University Animal Care and Use Committee and were performed in accordance with the 
2011 National Research Council Guidelines for the Care and Use of Mammals in Neuroscience 
and Behavioral Research. 
 
Apparatus. Each monkey’s cage contained an operant behavioral panel (“drinking panel”) that 
provided access to ethanol and food pellets during each session [38,61]. Each panel contained 
two drinking spouts, two sets of three lights (red, amber and green) positioned above each 
spout, a photo-optic switch positioned below one of the spouts and a centrally positioned 
opening containing a dowel. For all experimental sessions described below only one spout was 
active and provided ethanol; the monkeys had ad libitum access to water. Each panel was 
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connected to a 0.5-gallon ethanol bottle positioned atop a balance that continuously monitored 
its weight. Pulling the dowel activated a solenoid that allowed ethanol to flow. The ethanol was 
gravity-fed through the spout when it was displaced. Application of negative pressure could 
increase the rate of flow through the spout, allowing the monkey to have complete control over 
the volume she consumed. 
 
Ethanol and food self-administration. Sessions began at 11:00 am Monday through Friday with 
illumination of the lights above the ethanol spout. Throughout the six-hour session, ethanol was 
freely available when the dowel was pulled. Monkeys also self-administered food pellets under a 
fixed-ratio 1 schedule of reinforcement using the photo-optic switch. The daily food pellet 
allotment was divided into three “meals” which began 0, 120 and 240 minutes after the start of 
the session. Each meal lasted until 1/3 of the daily ration had been delivered or until the next 
meal period began. 
 
Acute drug administration. When daily ethanol intakes and food pellet deliveries were stable, a 
single dose of BU08028 (0.001-0.01 mg/kg), buprenorphine (0.003-0.056 mg/kg), SCH 221510 
(0.03-1.0 mg/kg), naltrexone (1.7-5.6 mg/kg) or vehicle was administered as an i.m. injection 30 
minutes prior to the start of alcohol access (60 minutes for BU08028). Typically, drugs were 
administered on Tuesdays and Fridays; vehicle was administered on Thursdays. Each monkey 
received each dose and vehicle at least twice, with replicates averaged within a monkey for 
analysis. 
 
Chronic drug administration. A similar approach to chronic drug treatment was used as was 
described previously [57,59]. Briefly, once ethanol intake and food pellet deliveries were stable, 
treatment with BU08028 or buprenorphine commenced. The starting dose was chosen based 
on each monkey’s sensitivity during acute dosing. A dose of BU08028 or buprenorphine was 
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administered 7 days per week at the same time each day (60 or 30 min prior to the start of the 
session, respectively). Drinking sessions were conducted five days per week (Monday through 
Friday). For BU08028, the initial dose was administered every other day for two weeks. This 
q.o.d. dosing regimen was used because the analgesic effects of BU08028 have a duration of 
action of ~48 hours [12]. After two weeks, effects indicated that daily dosing was necessary (see 
below). At the end of each week of treatment (i.e., Friday) the average of the last three days 
was calculated and compared to baseline using a t-test. A decision was made, based on the 
observed effects (or lack thereof) on ethanol intake and food-maintained responding, to either 
increase the dose of treatment drug or to keep it the same for the following week. When a dose 
was reached that resulted in persistent decreases in ethanol consumption (3-day average 
significantly below baseline), treatment was terminated and drinking was measured for an 
additional three weeks. 
 
Data Analysis. For acute studies, each drug was analyzed separately. Data for ethanol 
consumed and food pellets delivered were analyzed separately using a 1-way repeated-
measures ANOVA with a post-hoc Dunnett’s test to determine which doses produced effects 
significantly different from vehicle. For chronic studies, three time points (baseline, the week 
with the largest treatment drug effect and the third week after the end of treatment) were 
compared with a one-way ANOVA followed by a post-hoc Tukey’s multiple comparisons test. In 
all cases, differences were considered significant when p<0.05. 
 
Determination of blood ethanol concentrations (BECs). Several blood samples were collected 
during the months before drug testing began. For each monkey, 20-μL samples were collected 
from the saphenous vein 6 hours after the onset of the behavioral session. Blood samples were 
sealed in airtight vials containing 500 μL of ultrapure HPLC water and 20 μL of 200 mg% 
isopropanol (internal standard) and stored at −4˚C until assayed using gas chromatography 
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(Agilent 7890A GC system with G1888 Network Headspace Autosampler; Santa Clara, CA) 
supplied with a flame ionization detector and Agilent ChemStation integrator. Once all data had 
been collected, several more samples were collected in each monkey. The goal of these studies 
was to determine if ethanol metabolism changed over time, which could occur due to chronic 
administration of opioid compounds, long-term ethanol consumption, passage of time or a 
combination of factors. 
 
Drugs. Ethanol (95% ethyl alcohol; The Warner-Graham Company; Cockeysville, MD) was 
diluted each morning in water purified by reverse osmosis. BU08028 HCl was dissolved in a 
solution of dimethyl sulfoxide/10% (mass/vol) (2-hydroxypropyl)-β-cyclodextrin in a ratio of 3:97 
as previously described [63]. SCH 221510 (Tocris Bioscience; Bristol, United Kingdom) was 
prepared at a final concentration of 5 mg/ml in a vehicle (15% Tween80, 15% DMSO and 70% 
sterile water) as follows. Solid SCH 221510 was dissolved in 100% DMSO, then Tween80 was 
added. The mixture was heated and vortexed until clear, then water was added and the vial was 
heated/vortexed until the compound was dissolved. Naltrexone HCl and buprenorphine HCl 
(National Institute on Drug Abuse) were dissolved in sterile water. 
 
Results 
Effects of acute BU08028 or buprenorphine administration. When BU08028 was administered 
prior to the drinking session, there was a main effect of dose on ethanol intake (F3,12=13.33; Fig. 
1, top left) but not food pellets delivered (Fig. 1, bottom left). Post-hoc testing revealed that 
ethanol intake was significantly reduced by 0.01 mg/kg BU08028. Similarly, for buprenorphine 
(Fig. 1, right column), there was a main effect of dose on ethanol intake (F3,12=23.45) but not on 
food pellets delivered. Ethanol consumption was significantly decreased by 0.03 and 0.056 
mg/kg buprenorphine. 
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Effects of acute SCH 221510 or naltrexone administration. After administration of SCH 221510 
(Fig. 2, left column), there was a main effect of dose on ethanol intake (F2,8=8.30) but not food 
pellet deliveries. Ethanol intake was significantly reduced by 1.0 mg/kg SCH 221510. In 
contrast, after naltrexone administration (Fig. 2, right column), there was a main effect of drug 
on both ethanol intake (F3,12=10.16) and food pellet deliveries (F3,12=7.83). Both were decreased 
significantly after 3.0 and 5.6 mg/kg naltrexone. For all four drugs, no clear relationships were 
observed between baseline behavior (ethanol intake and food pellet deliveries) and individual 
differences in potency or efficacy of treatments. 
 
Effects of chronic BU08028 administration. Effects of chronic BU08028 treatment are depicted 
in Figure 3. For each monkey, a starting dose of BU08028 was selected based on the monkey’s 
sensitivity to BU08028 during acute studies. At the end of each treatment week, for each subject 
a decision was made based on observed effects (or lack thereof) on ethanol intake and food-
maintained responding to continue or increase the BU08028 dose for the next week. In four 
subjects a significant decrease in drinking was observed after one week of q.o.d administration. 
However, tolerance developed to this effect in all four animals. During q.o.d. dosing, it was 
common to see a greater effect on the day of drug administration than on the day drug was not 
given (e.g., R-1680). Based on these observations, BU08028 was subsequently administered 
daily. In R-1543, ethanol intake was decreased by 0.003 mg/kg BU08028 and further decreased 
when the dose was raised to 0.01 mg/kg. In R-1680, 0.01 mg/kg BU08028 produced a 
significant decrease in ethanol drinking during the first week which was maintained for two 
additional weeks of treatment. In R-1624 and R-1544, daily treatment with 0.017 mg/kg 
significantly decreased ethanol intake. In these four subjects, minimal or no effects on food-
maintained responding were observed during BU08028 treatment and ethanol intakes returned 
to baseline by week 2 after discontinuation of treatment. In contrast to these four subjects, no 
persistent effects of BU08028 were observed in R-1542. In this monkey, drinking tended to 
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decrease on day 4 and 5 of treatment but returned to baseline by day 7. Interestingly, this 
monkey was the most sensitive to the effects of BU08028 on food-maintained responding. In all 
monkeys, a transient decrease in food-maintained responding was observed upon termination 
of treatment. When ethanol drinking data from the week of the largest BU08028 effect were 
averaged across monkeys and compared to baseline and the third week after termination of 
treatment (Fig. 3, lower right), there was a significant main effect of condition (F2,8=19.54); post-
hoc testing indicated that the week of BU08028 treatment was significantly different from 
baseline. 
 
Effects of chronic buprenorphine administration. Effects of chronic buprenorphine treatment are 
depicted in Figure 4; the approach to testing was the same as that for BU08028. In R-1543 and 
R-1624, buprenorphine decreased ethanol intake during the first week of treatment. This effect 
was maintained or slightly increased when the dose was increased by one log unit over the 
subsequent six weeks. In R-1680, a significant decrease in ethanol intake was observed during 
treatment with 0.01 mg/kg buprenorphine treatment, but tolerance developed to this effect. 
Eventually treatment was terminated after a significant decrease was observed after two weeks 
of treatment with 0.3 mg/kg buprenorphine. In R-1544, tolerance developed to decreases that 
were observed during treatment with lower buprenorphine doses. In this monkey, however, no 
decrease was observed after two weeks of treatment with 0.3 mg/kg buprenorphine. Finally, as 
was observed with BU08028, R-1542 was the least sensitive to buprenorphine. Ethanol intake 
was slightly but significantly lower than baseline during the second week of treatment with 0.3 
mg/kg buprenorphine, but the difference was not significant when the dose was increased to 
0.56 mg/kg. When drinking data from the week of the largest buprenorphine effect were 
averaged across monkeys and compared to baseline and the third week after termination of 
treatment (Fig. 4, lower right), there was a significant main effect of condition (F2,8=7.57); post-
hoc testing indicated that the week of buprenorphine treatment was significantly different from 
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baseline. Across monkeys, other similarities to BU08028 treatment included a general lack of 
effect on food-maintained responding during drug administration except for R-1542 and some 
disruption in pellets delivered upon termination of treatment. Buprenorphine-induced decreases 
in ethanol drinking tended to persist longer after termination of treatment than did BU08028-
induced decreases. 
 
Ethanol pharmacokinetics did not change during the experiment. The relationship between 
ethanol consumed and resulting BEC was compared between samples collected in the months 
prior to initiation of drug testing and samples collected after all drug testing was completed. 
There was no significant difference in either the slopes or the y-intercepts of the two regression 
lines (Fig. 5).  
 
Discussion 
Efforts to develop analgesics safer than currently used opioids have identified “bifunctional” 
MOP/NOP receptor agonists, including BU08028, as drugs that can provide pain relief with 
reduced side effects [12-16]. Beyond their role in analgesia, and in part because the NOP 
peptide can inhibit the beta-endorphin neurons that may mediate alcohol abuse [64-65], NOP 
receptors have been investigated in rodent models of AUD. These studies have consistently 
demonstrated that stimulating NOP receptors can decrease the abuse-related effects of ethanol 
[22-30]. The present studies compared the effects of the MOP receptor agonist buprenorphine 
and the bifunctional MOP/NOP agonist BU08028 in rhesus monkeys who had free access to a 
4% ethanol solution six hours per day, five days per week. Monkeys consumed ~3.0 g/kg per 
day, equivalent to approximately ~12 drinks per day. Despite this relatively high ethanol intake, 
the lack of observed withdrawal signs on weekends indicated that monkeys were not physically 
dependent on ethanol. Moreover, the relationship between ethanol consumed and resulting 
BECs did not change over the course of these experiments, indicating that no metabolic 
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tolerance occurred. In addition, neither the duration of monkeys’ menstrual cycles nor pattern of 
drinking across the cycle was altered during these experiments [62]. 
 
Acute administration of both BU08028 and buprenorphine decreased ethanol drinking, 
consistent with previous studies of NOP receptor agonists and buprenorphine in rodents [22-
30,66] and buprenorphine in monkeys [67]. Acutely, BU08028 was ~0.5 log units more potent 
that buprenorphine. Importantly, decreases in ethanol drinking were observed at doses that did 
not significantly alter food-maintained responding. The lack of effect of buprenorphine on food-
maintained responding is consistent with most studies in nonhuman primates [e.g., 68,69], 
although effects on food-maintained responding have been observed under some conditions 
depending on the monkeys’ experimental history and the schedule of reinforcement used [70-
72]. The behavioral selectivity observed in the present study supports the conclusion that 
decreases in drinking were due to reductions in the reinforcing/motivational effects of ethanol 
rather than to sedation, motor impairments or other behavioral effects.  
 
A critical aspect of testing potential medications is the assessment of effects of chronic 
administration [55,56]. In the context of this study, it was important to assess whether tolerance 
would develop to the ability of BU08028 and buprenorphine to decrease ethanol drinking and 
whether any adverse effects would emerge. In four of five monkeys, BU08028 significantly 
decreased ethanol intake without tolerance development. Buprenorphine produced decreases in 
ethanol drinking in the same four subjects, although the effect was modest in one subject (R-
1680) and in another subject (R-1544) tolerance developed. In chronic studies, BU08028 was 
more potent in most monkeys and somewhat more efficacious over the range of doses tested. 
Termination of drug treatment resulted in temporary disruption of food-maintained responding 
and a gradual return to baseline levels of ethanol consumption, although reductions of drinking 
persisted longer after buprenorphine treatment. Interestingly, in R-1542, no persistent 
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decreases in ethanol consumption were produced by either drug, despite disruption of food-
maintained responding. No distinguishing characteristics have been identified to indicate why 
results in this monkey differed from the other four subjects. 
 
As described above, BU08028 and buprenorphine have been characterized in vitro as MOP and 
NOP receptor partial agonists [16]. However, the contribution of NOP receptors to the 
behavioral effects of buprenorphine appears to differ between rodents and monkeys. In contrast 
to results in rodents [54,73], blocking NOP receptors in rhesus monkeys did not alter 
buprenorphine-induced antinociception, respiratory depression or scratching [39]. Thus, 
although a role for NOP receptors has been demonstrated in the ability of buprenorphine to 
decrease ethanol drinking in rats [25], it is likely that its effects on ethanol consumption in the 
present and only previous nonhuman primate study [67] resulted primarily from activity at MOP 
receptors. The observed decreases are consistent with previous studies of the effects of 
buprenorphine on alcohol consumption. In a previous rodent study [25], ethanol drinking was 
increased by low doses of buprenorphine, whereas higher buprenorphine doses decreased 
ethanol intake. The authors suggested that this biphasic effect resulted from stimulation of MOP 
at lower doses and NOP at higher doses. That study used as subjects rats genetically bred for 
high ethanol intake and have upregulated NOP receptor function [74,75]. In another study using 
outbred rats, low-to-intermediate buprenorphine doses increased ethanol intakes under some 
conditions and decreased drinking under others [66]. In addition to rat strain there were several 
differences in experimental design that may have contributed to the discrepant effects including 
extent of daily ethanol access and time before the session that buprenorphine was 
administered. In contrast, in the present and previous nonhuman primate studies [67], lower 
buprenorphine doses did not increase ethanol intakes. Nonetheless, in all four studies as well 
as one other rodent study that tested only one dose [76], higher doses of buprenorphine 
decreased ethanol drinking. 
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Taken together the present data suggest that the ability of buprenorphine to decrease ethanol 
drinking is shared by the bifunctional MOP/NOP receptor agonist BU08028. In acute studies, 
BU08028 was more potent than buprenorphine. In addition, in chronic studies, BU08028 was 
more potent in most monkeys and somewhat more effective. In general the findings support the 
view developed from studies of the analgesic effects of these drugs that combining NOP and 
low-efficacy MOP agonists could prove advantageous compared to MOP agonists alone [12-
16]. For example, addition of NOP receptor activity could permit use of lower doses of a MOP 
receptor agonist, enhance efficacy in decreasing alcohol drinking, widen the therapeutic 
window, reduce the rate or magnitude of tolerance development and reduce side effects 
including abuse potential. For example, although remifentanil, oxycodone and buprenorphine 
maintained self-administration in rhesus monkeys under a progressive-ratio schedule, 
BU088028 did not function as a reinforcer [12,13]. 
 
Future studies will be necessary to characterize the relative contribution of MOP and NOP 
receptors to the therapeutic effects of bifunctional MOP/NOP agonists like BU08028. In the 
present studies, the acute effects of SCH 221510, a NOP receptor agonist with 217-fold 
selectivity in binding and 58-fold selectivity in stimulating NOP versus MOP receptors [11], were 
similar to those of buprenorphine and BU08028. This result may suggest that NOP receptor 
stimulation alone is sufficient to reduce alcohol drinking, in agreement with rodent studies 
[26,27,30]. However, the dose of SCH 221510 required to reduce ethanol drinking was higher 
than the dose needed to produce antinociception in a previous study [77]. Although the 
discrepancy might be explained by different efficacy requirements between the two assays, the 
large potency difference could also indicate that the reduction in drinking resulted from activity 
at other receptors. Additional study of NOP receptor-selective agonists, administered 
chronically, and combination studies of bifunctional MOP/NOP receptor agonists with NOP and 
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MOP receptor antagonists will be required to fully understand the relative contributions of MOP 
and NOP receptors to the behavioral effects of bifunctional agonists. Moreover, it will be 
important to assess the involvement of KOP receptors, which can mediate and modulate the 
abuse-related effects of ethanol [78-80]. This is particularly important because buprenorphine 
and BU08028 are KOR antagonists with relatively high affinity (2.5 ± 1.2 nM and 5.6 ± 1.3 nM, 
respectively [16]). Finally, it will be important to examine whether MOP/NOP and NOP receptor 
agonists selectively decrease alcohol intake in males; sex differences have been observed in 
the effects of low-efficacy MOP receptor agonists on antinociception and on rates of food-
maintained responding [71,81].  
 
Due to the enormous need for non-abusable analgesics in response to the ongoing epidemic of 
opioid abuse, it is likely that clinical development of bifunctional MOP/NOP receptor agonists will 
be prioritized. NOP-acting drugs were included in the list of NIDA’s medication development 
priorities as part of the NIH HEAL (Helping to End Addiction Long-term) Initiative [82]. The 
results of the present studies extend promising results from rodent models that suggest that 
such drugs are candidates as novel medications for AUD.  
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Figure Legends. 
Figure 1. Effects of acute BU08028 and buprenorphine on ethanol drinking and food 
pellet deliveries. Top row, ethanol intake. Bottom Row, food pellet deliveries. Bars represent 
mean ± SEM, n=5; *, p<0.05 compared to vehicle (V). 
 
Figure 2. Effects of acute SCH 221510 and naltrexone on ethanol drinking and food pellet 
deliveries. Top row, ethanol intake. Bottom Row, food pellet deliveries. Bars represent mean ± 
SEM, n=5; *, p<0.05 compared to vehicle (V). 
 
Figure 3. Effects of chronic BU80828 treatment on ethanol drinking and food pellet 
deliveries. For first five graphs, left ordinate: ethanol (EtOH) intake (circles; filled circles 
represent data collected during BU08028 treatment); right ordinate: food pellets delivered 
(squares); abscissa: day of exposure to each condition, which is indicated across the top of 
each panel. Point above BL represents mean (±SD) ethanol dose consumed at baseline before 
BU08028 treatment. Vertical dotted lines indicate days during q.o.d treatment on which 
BU08028 was administered. Asterisks indicate weeks when average ethanol intake differed 
significantly form baseline. Lower right: mean (±SEM) ethanol intake at baseline, during the 
week of the maximum BU08028 effect and during the third week after BU08028 treatment 
ended. n=5; *, p<0.05. 
 
Figure 4. Effects of chronic buprenorphine treatment on ethanol drinking and food pellet 
deliveries. For first five graphs, left ordinate: ethanol (EtOH) intake (circles; filled circles 
represent data collected during buprenorphine [BUPR] treatment); right ordinate: food pellets 
delivered (squares); abscissa: day of exposure to each condition, which is indicated across the 
top of each panel. Point above BL represents mean (±SD) ethanol dose consumed at baseline 
before buprenorphine treatment. Vertical dotted lines indicate days during q.o.d treatment on 
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which buprenorphine was administered. Asterisks indicate weeks when average ethanol intake 
differed significantly form baseline. Lower right: mean (±SEM) ethanol intake at baseline, during 
the week of the maximum buprenorphine effect and during the third week after BU08028 
treatment ended. n=5; *, p<0.05. 
 
Figure 5. Relationship between amount of ethanol consumed and blood ethanol 
concentrations (BEC). Points represent single determinations from individual subjects (n=5), 
one shape per subject. Open symbols and dashed line depict samples collected before the drug 
treatments began; solid symbols and lines represent data collected after the last drug treatment. 
Lines represent best fit results of linear regression. 
 
 





